A Sharply Defined Pattern of Central Retinal Thinning
An old quilt, patched and repatched over the years, can end up with one square that's faded almost entirely to white while every other patch around it keeps its original colour and pattern intact. Under retinal examination, central areolar choroidal dystrophy creates a comparably distinctive picture — a clearly bordered patch of atrophy sitting right beneath the macula, with the retina and choroid nearby left essentially undisturbed. That unusually crisp border is usually what a specialist notices before anything else.
In Zimbabwe, this diagnosis usually surfaces when a patient in their thirties or forties visits for an unconnected eye concern, and the exam turns up a pale, unusually well-defined patch — something a sharp-eyed local doctor flags immediately as out of place for someone at that stage of life.
Most people only realise something has shifted by comparing how things used to be — a menu that once read effortlessly now demands real concentration, or they find themselves tilting their head to nudge a face slightly away from dead centre. Over time a sharply bordered dark or grey area settles right into the middle of a person's vision, though ordinary activities — crossing a full room, locating a doorway — remain entirely manageable, since the disease only touches that narrow central zone and leaves vision in low light completely alone.
Most confirmed cases trace back to a defect in the PRPH2 gene, which under normal conditions builds a structural protein that photoreceptor cells depend on to hold their shape and function properly. Once that protein fails, three closely stacked layers beneath the macula — the choriocapillaris, the retinal pigment epithelium, and the photoreceptors sitting above them — break down as a unit, though the damage stays tightly confined to that one small region without spreading further. This tends to run in families as a dominant trait, showing up generation after generation.
What draws attention on examination is just how unusually crisp the border of the atrophic area looks, almost as though it had been traced with a straightedge, and fundus autofluorescence remains the best tool available for mapping that boundary precisely. OCT reveals how much photoreceptor tissue survives right at the very edge — often the single most useful detail for planning ahead — and a largely normal ERG reading offers real reassurance, since it confirms the damage has genuinely stayed contained rather than spreading. A PRPH2 genetic test is what finally rounds off the diagnostic work.
Instead of following a rigid schedule, we let the pace at which the atrophic zone is actually growing shape the plan, judged through repeated imaging spaced over time rather than a single snapshot. Qualifying patients are considered for regenerative stem cell therapy, aimed at protecting retina still working near the edge of the affected area, and as that central blind spot takes clearer form, we help develop practical low-vision approaches around each person's specific pattern of loss.
Not at all — that's actually exactly what we'd expect rather than any cause for concern. This condition only touches a small central area and spares the rod cells responsible for night vision entirely, so seeing in low light usually stays just as dependable even while reading and recognising faces gets harder.
There's no predictable endpoint to it — a portion of patients stay nearly the same across ten years, while others notice movement within a considerably shorter window. It's precisely because of that unpredictability that we rely on repeat imaging rather than assuming any single growth rate.
The resemblance can be striking, but the two arise from completely different causes at very different points in life — yours from an inherited gene fault decades ahead of schedule, hers from ordinary age-related changes arriving much later. What genuinely distinguishes the two is a combination of genetic testing and the age things first began.
For most patients, that's unlikely — everyday mobility and sense of direction generally hold up fine, since the disease sticks to one defined central area rather than spreading into the wider visual field that guides how we navigate day to day.